The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its geographic reach.

On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of ...

The research, published in the Canadian Medical Association Journal (CMAJ) Monday, found that 32.7 per cent of Canadians ...

An Ozempic user has revealed what they believe is a 'terrifying' side effect of upping their Ozempic dose. Falling into the category of GLP-1 medications, Ozempic is FDA-approved for type two diabetes ...

SINGAPORE - Media OutReach Newswire - 12 July 2025 - A significant advancement in weight management has arrived for Singaporeans. Novo Nordisk, a global healthcare company focused on defeating serious ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

Regarding injection site rotation, alternate between different areas like the abdomen, thigh, or upper arm to prevent ...

Danish pharmaceutical company Novo Nordisk has officially launched its once-weekly injectable weight management drug, Wegovy® ...

Data from a limited number of trials hint that GLP-1 use might improve erectile dysfunction and testosterone levels for men, but more research is needed to provide a clearer picture, researchers ...

Imugene is tapping the market for up to $35 million, while Clever Culture Systems and Compumedics are soaring on positive ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in.  | Novo ...